Re: USA ZHCLF investors
in response to
by
posted on
Nov 02, 2022 11:56AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Currently the way I understand this is ZCC has approx. 75 m shareholders. Those shareholders own a 6% to 12 % RPS of Apabetalone revenues and 75 m shares in Zenith Epigenetics.
Since ZCC was created(2013), Zenith Epigenetics has issued 63 m shares in private placements to raise operating capital.
If Zenith was sold for "X" $ per share, ZCC would hold the value of 75 m x "X" $ . The 63 m shareholders would be paid out.
ZCC share holders would be at the mercy of the board to determine the amount of a dividend that would be paid.
If Zenith Epigenetics was to sell just ZEN 3694 then that money would go into general revenue of Zenith Epigenetics and raise the value of it's shares. ZCC currently has a majority ownership in Zenith Epigenits and could vote to distribute some $ from the sale as a dividend to all 138 m shareholder but would not be obligated to do that.
Zenith Epigenetics may choose to use that money to procure a Nasdaq listing and then shareholders would be free to do as the please with their shares but ZCC would still be making discissions on behalf of the 75 m shares it holds in Zenith Epigenetics.
The confusion was created when the OTC market started using the symbol ZHCLF and it was picked up by various platforms as a means to identify the 63 m shares issued by Zenith Epigenetics.
My concern is that ZCC currently has a majority interest in Zenith Epigenetics but as time passes and more shares are issued, we (ZCC sharholders) could lose control of Zenith Epigenetics.
So there are a couple of possibilities to consider,
1) BP makes an offer to buy the rights to Zen 3964 which gives Zenith Epigenetics cash.
2) BP buys the whole kettle of fish and then ZCC will get cash to distrubite to it's shareholders. This is what I perfer as it is the quickest way for me to get some money out of this investment challenge.
There may be more long term upside value in #1 if they uses some of the cash to get a Nasdaq listing and move along some of the other drugs in the pipeline.
I beleive time is against ZCC share holders who want the sale of the whole of Zenith Epigenetics.
Just the way I see it and am open to discussion.